TKD Stock Chart & Stats
€31.45
€0.44(1.44%)
At close: 4:00 PM EDT
€31.45
€0.44(1.44%)
Day’s Range― - ―
52-Week Range€22.45 - €33.53
Previous CloseN/A
Volume39.00
Average Volume (3M)396.00
Market Cap
€52.74B
Enterprise Value€12.75T
Total Cash (Recent Filing)€527.58B
Total Debt (Recent Filing)€4.94T
Price to Earnings (P/E)51.8
Beta0.21
Next Earnings
Oct 29, 2026EPS Estimate
0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)114.22
Shares Outstanding1,602,141,400
10 Day Avg. Volume777
30 Day Avg. Volume396
Financial Highlights & Ratios
PEG Ratio0.60
Price to Book (P/B)1.15
Price to Sales (P/S)1.98
P/FCF Ratio11.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€39.40Price Target Upside25.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.7
Revenue Forecast (FY)€26.50B
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationSubstantial operating and free cash flow gives Takeda internal funding capacity for research, launches, debt management, and shareholder distributions. Although recent cash flow softened, the absolute level supports resilience and allows the company to pursue growth without relying solely on external financing.
Improving LeverageImproving leverage and a growing equity base strengthen Takeda’s financial flexibility as it invests in new medicines and commercial launches. A more manageable capital structure can reduce balance-sheet strain and preserve the ability to fund strategic priorities through changing pharmaceutical cycles.
Pipeline And Launch PotentialMultiple late-stage assets and planned launches create potential avenues for replacing mature-product revenue and broadening Takeda’s growth base. Regulatory progress, differentiated clinical data, and advancing launch readiness increase the possibility that current R&D investment converts into durable future sales.
Bears Say
Underlying Revenue SoftnessThe constant-currency decline indicates that reported growth is not fully reflecting underlying business expansion and that foreign exchange translation is masking operational softness. Continued pressure could limit organic revenue momentum and make it harder for Takeda to grow earnings independently of currency movements.
Mature Product ErosionGeneric competition and loss of exclusivity can create durable revenue pressure because established products may decline faster than replacement launches scale. This raises the execution burden on Takeda’s pipeline and requires sustained successful commercialization to prevent portfolio-level erosion.
Thin Earnings ReturnsThin and volatile bottom-line profitability means Takeda is converting a relatively modest portion of revenue and capital into shareholder returns. This can reduce financial resilience, constrain internally funded growth, and leave earnings more exposed to costs, non-operating items, and product-cycle changes.
TKD FAQ
What was Takeda Pharmaceutical Co Ltd’s price range in the past 12 months?
Takeda Pharmaceutical Co Ltd lowest stock price was €22.45 and its highest was €33.53 in the past 12 months.
What is Takeda Pharmaceutical Co Ltd’s market cap?
Takeda Pharmaceutical Co Ltd’s market cap is €52.74B.
When is Takeda Pharmaceutical Co Ltd’s upcoming earnings report date?
Takeda Pharmaceutical Co Ltd’s upcoming earnings report date is Oct 29, 2026 which is in 16 days.
How were Takeda Pharmaceutical Co Ltd’s earnings last quarter?
Takeda Pharmaceutical Co Ltd released its earnings results on Jul 30, 2026. The company reported €0.405 earnings per share for the quarter, beating the consensus estimate of €0.308 by €0.098.
Is Takeda Pharmaceutical Co Ltd overvalued?
According to Wall Street analysts Takeda Pharmaceutical Co Ltd’s price is currently Undervalued.
Does Takeda Pharmaceutical Co Ltd pay dividends?
Takeda Pharmaceutical Co Ltd does not currently pay dividends.
What is Takeda Pharmaceutical Co Ltd’s EPS estimate?
Takeda Pharmaceutical Co Ltd’s EPS estimate is 0.26.
How many shares outstanding does Takeda Pharmaceutical Co Ltd have?
Takeda Pharmaceutical Co Ltd has 1,602,141,400 shares outstanding.
What happened to Takeda Pharmaceutical Co Ltd’s price movement after its last earnings report?
Takeda Pharmaceutical Co Ltd reported an EPS of €0.405 in its last earnings report, beating expectations of €0.308. Following the earnings report the stock price went down -3.137%.
Which hedge fund is a major shareholder of Takeda Pharmaceutical Co Ltd?
Currently, no hedge funds are holding shares in DE:TKD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Takeda Pharmaceutical Co Ltd
Takeda Pharmaceutical Company Limited is a global biopharmaceutical enterprise engaged in the discovery, development, manufacturing, marketing, and out-licensing of various medical products. The company's operations span Japan, the United States, Europe, Canada, Latin America, Russia, and other regions across Asia and internationally. Takeda concentrates its efforts on key therapeutic areas such as gastroenterology, rare diseases, plasma-derived therapies, oncology, and neuroscience. Its extensive product range includes well-known brands like Entyvio, Takhzyro, Velcade, and Vyvanse. To advance its pipeline and innovation, Takeda actively fosters numerous collaborations, in-licensing agreements, research partnerships, and strategic alliances with a diverse array of organizations, including academic institutions like the University of Texas MD Anderson Cancer Center and biotech firms such as Neurocrine Biosciences, Inc. and Arrowhead Pharmaceuticals Inc. Established in 1781, the company maintains its headquarters in Tokyo, Japan.
TKD Company Deck
TKD Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a mix of modest near-term CER declines and cash-flow timing effects against substantial positive developments: strong FX-driven reported results, confirmation of transformation-led funding for launches, multiple imminent regulatory and commercial milestones (ORZEYFUL approval in China; rusfertide priority review; superior zasocitinib data), and a robust late-stage pipeline with several programs moving to pivotal stages. While Q1 contained some one-time impacts, transitional investment effects and product-specific headwinds, the combination of pipeline momentum, launch readiness and a maintained full-year financial outlook suggests the company is positioned to convert R&D progress into revenue growth later in the year.View all DE:TKD earnings summariesTKD Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
€39.40
▲(25.26% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Sumitomo Dainippon Pharma Co
―
Eisai Co
―
―
Shionogi & Co
―
Nippon Shinyaku Co., Ltd.
―











